Sign up to save your podcasts
Or
Share 5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
5-Minute Journal Club Issue 8 with Dr Rinath M Jesselsohn: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast Cancer
Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:
- Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00)
- Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract
- Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13)
- Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract
- Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.
- Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06)
- VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.
- Selective review of trials of oral SERDs in the adjuvant setting (11:27)
- A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054
CME information and select publications
View all episodes
By Dr Neil Love
4.6
108108 ratings
Featuring an interview with Dr Rinath M Jesselsohn, including the following topics:
- Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00)
- Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract
- Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13)
- Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract
- Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.
- Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06)
- VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.
- Selective review of trials of oral SERDs in the adjuvant setting (11:27)
- A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054
CME information and select publications
More shows like Research To Practice | Oncology Videos
View all
Gastrointestinal Cancer Update
17 Listeners
Lung Cancer Update
31 Listeners
Prostate Cancer Update
14 Listeners
Breast Cancer Update
63 Listeners
Gynecologic Oncology Update
11 Listeners
Hematologic Oncology Update
72 Listeners
Dermatologic Oncology Update
0 Listeners
NEJM This Week
318 Listeners
JAMA Clinical Reviews
487 Listeners
Hidden Brain
43,475 Listeners
ASCO Daily News
57 Listeners
The Curbsiders Internal Medicine Podcast
3,323 Listeners
ASCO Guidelines
43 Listeners
The Dr. Hyman Show
9,359 Listeners
OncLive® On Air
21 Listeners
Oncology Today with Dr Neil Love
53 Listeners
Two Onc Docs
166 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
38 Listeners